BCYC BICYCLE THERAPEUTICS plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCYC

Price (delayed)

$24.58

Market cap

$1.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.42

Enterprise value

$633.36M

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short ...

Highlights
BCYC's revenue has soared by 168% YoY and by 54% QoQ
BICYCLE THERAPEUTICS's gross profit has surged by 168% YoY and by 54% QoQ
BCYC's equity is up by 46% year-on-year but it is down by 4% since the previous quarter
BCYC's net income is down by 35% YoY but it is up by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bicycletherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BCYC
Market
Shares outstanding
42.78M
Market cap
$1.05B
Enterprise value
$633.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.94
Price to sales (P/S)
25.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.22
Earnings
Revenue
$41.61M
EBIT
-$163.16M
EBITDA
-$156.52M
Free cash flow
-$85.93M
Per share
EPS
-$4.42
Free cash flow per share
-$2.02
Book value per share
$8.36
Revenue per share
$0.98
TBVPS
$12.86
Balance sheet
Total assets
$547.14M
Total liabilities
$191.1M
Debt
$38.85M
Equity
$356.05M
Working capital
$466.45M
Liquidity
Debt to equity
0.11
Current ratio
10.42
Quick ratio
10.02
Net debt/EBITDA
2.67
Margins
EBITDA margin
-376.1%
Gross margin
100%
Net margin
-404.1%
Operating margin
-432.2%
Efficiency
Return on assets
-30.1%
Return on equity
-49.3%
Return on invested capital
-271.1%
Return on capital employed
-32.8%
Return on sales
-392.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCYC stock price

How has the BICYCLE THERAPEUTICS stock price performed over time
Intraday
-0.45%
1 week
8.14%
1 month
5.4%
1 year
12.6%
YTD
35.95%
QTD
-1.29%

Financial performance

How have BICYCLE THERAPEUTICS's revenue and profit performed over time
Revenue
$41.61M
Gross profit
$41.61M
Operating income
-$179.86M
Net income
-$168.16M
Gross margin
100%
Net margin
-404.1%
BCYC's revenue has soared by 168% YoY and by 54% QoQ
BICYCLE THERAPEUTICS's gross profit has surged by 168% YoY and by 54% QoQ
BCYC's net margin is up by 50% year-on-year and by 40% since the previous quarter
The operating margin has grown by 49% YoY and by 39% from the previous quarter

Growth

What is BICYCLE THERAPEUTICS's growth rate over time

Valuation

What is BICYCLE THERAPEUTICS stock price valuation
P/E
N/A
P/B
2.94
P/S
25.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.22
BICYCLE THERAPEUTICS's EPS has increased by 13% from the previous quarter but it has decreased by 6% YoY
BCYC's equity is up by 46% year-on-year but it is down by 4% since the previous quarter
The stock's P/B is 13% above its last 4 quarters average of 2.6 but 11% below its 5-year quarterly average of 3.3
BCYC's revenue has soared by 168% YoY and by 54% QoQ
The P/S is 44% less than the 5-year quarterly average of 44.7 and 13% less than the last 4 quarters average of 28.9

Efficiency

How efficient is BICYCLE THERAPEUTICS business performance
The company's return on invested capital has shrunk by 74% YoY and by 11% QoQ
BICYCLE THERAPEUTICS's ROS has soared by 50% YoY and by 40% from the previous quarter
The ROE has grown by 15% from the previous quarter but it has contracted by 11% YoY
The ROA has grown by 12% from the previous quarter but it has contracted by 3.1% YoY

Dividends

What is BCYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCYC.

Financial health

How did BICYCLE THERAPEUTICS financials performed over time
BICYCLE THERAPEUTICS's total assets is 186% more than its total liabilities
BCYC's current ratio is up by 45% year-on-year and by 29% since the previous quarter
BICYCLE THERAPEUTICS's quick ratio has increased by 43% YoY and by 27% QoQ
BCYC's debt is 89% smaller than its equity
BCYC's equity is up by 46% year-on-year but it is down by 4% since the previous quarter
BICYCLE THERAPEUTICS's debt to equity has decreased by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.